Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study

Lauritsen, Jakob; Bandak, Mikkel; Kreiberg, Michael; Skøtt, Julie Wang; Wagner, Thomas; Rosenvilde, Josephine; Dysager, Lars; Agerbæk, Mads; Daugaard, Gedske

doi:10.1007/s11764-020-00944-1

Cited by 18 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported that smoking was the risk factor for CIPN development [10][11][12][13]. The result of the current study is consistent with this previous nding.…”

Section: Discussionsupporting

confidence: 93%

Predictors of the Development of Nab-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: Post Hoc Analysis of a Prospective, Phase II, Self-Controlled Clinical Trial

Kanbayashi

Sakaguchi

Ishikawa

et al. 2022

Preprint

View full text Add to dashboard Cite

In a previous study, we showed that cryotherapy and compression therapy have comparable efficacy in preventing nab-paclitaxel-induced peripheral neuropathy. However, even with cryotherapy or compression therapy, there were patients with National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade ≥ 2 and/or Patient Neurotoxicity Questionnaire (PNQ) grade ≥ D peripheral neuropathies. Therefore, this post hoc analysis was performed to identify predictors of nab-paclitaxel-induced peripheral neuropathy. The clinical data in this post hoc analysis were the data of 38 breast cancer patients receiving chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) at our outpatient chemotherapy center from August 2017 to March 2019. The number of patients was analyzed assuming that there were data for 76 hands. Variables related to the development of nab-PTX-induced peripheral neuropathy were used for regression analysis. Multivariate ordered logistic regression analysis was performed to identify predictors for the development of nab-PTX-induced peripheral neuropathy. Significant factors included smoking history [odds ratio (OR) = 4.64, 95% confidence interval (CI) = 1.60-13.5; P = 0.0048] with neuropathy evaluated by CTCAE, body mass index (BMI) (OR = 1.13, 95% CI = 1.01-1.26; P = 0.039) with neuropathy evaluated by PNQ (sensory), and smoking history (OR = 3.80, 95% CI = 1.40-10.30; P = 0.0087) and age (OR = 1.06, 95% CI = 1.01-1.11; P = 0.012) with neuropathy evaluated by PNQ (motor). In conclusion, smoking history, BMI and age were identified as significant predictors of the development of nab-PTX-induced-peripheral neuropathy.

show abstract

“…Several studies have reported that smoking was the risk factor for CIPN development [10][11][12][13]. The result of the current study is consistent with this previous nding.…”

Section: Discussionsupporting

confidence: 93%

Predictors of the Development of Nab-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: Post Hoc Analysis of a Prospective, Phase II, Self-Controlled Clinical Trial

Kanbayashi

Sakaguchi

Ishikawa

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that smoking was the risk factor for CIPN development [11][12][13][14]. The result of the current study is consistent with this previous nding.…”

Section: Discussionsupporting

confidence: 93%

Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: Sub-analysis of a prospective, self-controlled trial

Kanbayashi

Sakaguchi

Ishikawa

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose In a previous study, we showed that cryotherapy and compression therapy have comparable efficacy in preventing nab-paclitaxel-induced peripheral neuropathy. However, even with cryotherapy or compression therapy, there were patients with National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade ≥ 2 and/or Patient Neurotoxicity Questionnaire (PNQ) grade ≥ D peripheral neuropathies. Therefore, a sub-analysis was performed to identify predictors of nab-paclitaxel-induced peripheral neuropathy. Methods The clinical data in this sub-analysis were the data of 38 breast cancer patients receiving chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) at our outpatient chemotherapy center from August 2017 to March 2019. The number of patients was analyzed assuming that there were data for 76 hands. Variables related to the development of nab-PTX-induced peripheral neuropathy were used for regression analysis. Multivariate ordered logistic regression analysis was performed to identify predictors for the development of nab-PTX-induced peripheral neuropathy. Results Significant factors included smoking history [odds ratio (OR) = 4.64, 95% confidence interval (CI) = 1.60–13.5; P = 0.0048] with neuropathy evaluated by CTCAE, body mass index (BMI) (OR = 1.13, 95% CI = 1.01–1.26; P = 0.039) with neuropathy evaluated by PNQ (sensory), and smoking history (OR = 3.80, 95% CI = 1.40–10.30; P = 0.0087) and age (OR = 1.06, 95% CI = 1.01–1.11; P = 0.012) with neuropathy evaluated by PNQ (motor). Conclusions Smoking history, BMI and age were identified as significant predictors of the development of nab-PTX-induced-peripheral neuropathy.

show abstract

Section: Discussionsupporting

confidence: 85%

“…Long-lasting CIPN symptoms appear common also in other groups of long-term cancer survivors, such as survivors of childhood leukemia and testicular cancer [43,44]. With increasing CIPN symptom burden we found both significantly reduced physical and mental QoL, confirming studies from other cohorts of cancer survivors [43,45]. Neuropathy symptoms seem to impact the physical aspects of QoL more than they affect mental well-being, as previously also shown for short-term complaints after treatment in non-Hodgkin's lymphoma [46].…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life

et al. 2021

View full text Add to dashboard Cite

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin's lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL). Material and methods: A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population (n ¼ 606). CIPN associated factors were identified by linear regression analysis. Results: Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities (p < 0.001) and female gender (p ¼ 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities (p < 0.001) and caseness (p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL (p < 0.001). Conclusion: HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.

show abstract

Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study

Cited by 18 publications

References 32 publications

Predictors of the Development of Nab-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: Post Hoc Analysis of a Prospective, Phase II, Self-Controlled Clinical Trial

Predictors of the Development of Nab-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: Post Hoc Analysis of a Prospective, Phase II, Self-Controlled Clinical Trial

Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: Sub-analysis of a prospective, self-controlled trial

Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life

Contact Info

Product

Resources

About